$31.34—Stale · unknown old
NYSE • Last print unknown ago
$31.34—Stale · unknown old
IMS Health Holdings, Inc. specializes in healthcare information services, providing analytics and insights to pharmaceutical companies and healthcare providers. Its competitive position is bolstered by a comprehensive database of healthcare data, enabling clients to make informed decisions in drug development and market access strategies.
IMS generates revenue primarily through subscription-based analytics services, which provide valuable insights derived from extensive healthcare data. The company's strong relationships with pharmaceutical clients give it pricing power, while its proprietary data sets create a competitive advantage in the market.
Changes in pharmaceutical spending on data analytics
Regulatory changes impacting healthcare data usage
Adoption rates of new software solutions
Mergers and acquisitions within the healthcare sector
Technological disruption from emerging data analytics platforms
Regulatory changes affecting data privacy and usage
Increased competition from new entrants in healthcare analytics
Potential loss of key clients to competitors
High debt-to-equity ratio (2.67) may limit financial flexibility
Potential liquidity risks if cash flow does not meet operational needs
moderate - IMS's business is somewhat linked to GDP as healthcare spending tends to be resilient, but fluctuations in pharmaceutical budgets can impact revenue.
Interest rates affect IMS primarily through the cost of financing for potential acquisitions and investments in technology. Higher rates could compress margins if borrowing costs rise significantly.
minimal - IMS operates with a relatively low level of debt, reducing its sensitivity to credit market fluctuations.
growth - investors are likely attracted to IMS for its strong revenue growth and high return on equity (ROE) of 26.8%.
moderate - the stock has shown stable performance historically, but could experience volatility due to sector-specific risks.